Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancer

Nature Clinical Practice Oncology

Volumn 1, Issue 1, 2004, Pages 44-50

  Pusztai, Lajos ^a   Gianni, Luca ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Gene expression profiling; Pharmacogenomics predictive markers; Response prediction

Indexed keywords

CYCLOPHOSPHAMIDE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GLYCOPROTEIN P; PACLITAXEL; PROTEIN BCL 2; PROTEIN P53;

ACCURACY; ANALYTIC METHOD; ASPIRATION BIOPSY; BREAST CANCER; BREAST SURGERY; CANCER SURVIVAL; DIAGNOSTIC VALUE; DNA MICROARRAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; MARKER GENE; MEDICAL DECISION MAKING; NEEDLE BIOPSY; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; PREDICTION; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; TREATMENT OUTCOME;

BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOADJUVANT THERAPY; PREOPERATIVE CARE; TUMOR MARKERS, BIOLOGICAL;

EID: 20444451252     PISSN: 17434254     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncponc0025     Document Type: Review

References (45)

1. Early Breast Cancer Trialists' Collaborative Group (1999) Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 352: 930-942
2. Fisher B et al. (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685
3. Rouzier R et al. (2002) Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20: 1304-1310
4. Buchholz TA et al. (2002) Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 53: 880-888
5. Chen AM et al. (2004) Breast conservation after neoadjuvant chemotherapy: the MD Anderson Cancer Center experience. J Clin Oncol 22: 2303-2312
6. Bonadonna G et al. (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16: 93-100
7. Kaufmann M et al. (2003) International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21: 2600-2608
8. Smith IC et al. (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20: 1456-1466
9. National Comprehensive Cancer Network, Breast Cancer Practice Guidelines (http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf)
10. Goldhirsch A et al. (2003) Meeting highlights: updated international expert consensus panel on the primary therapy of early breast cancer. J Clin Oncol 21: 1-9
11. Abu-Farsakh H et al. (1995) Pathologic predictors of tumor response to preoperative chemotherapy in locally advanced breast carcinoma. Breast J 1: 96-101
12. Colleoni M et al. (2000) Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 11: 1057-1059
13. Kuerer HM et al. (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-469
14. Bast RC Jr et al. (2001) 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19: 1865-1878
15. Chang J et al. (1999) Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17: 3058-3063
16. Ellis P et al. (1998) Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 16: 107-114
17. Zhang F et al. (2003) Correlation between HER2 expression and response to neoadjuvant FAC chemotherapy in breast cancer. Cancer 97: 1758-1765
18. Rozan S et al. (1998) No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 79: 27-33
19. Hortobagyi GN et al. In 2002 ASCO Annual Meeting Summaries; 2002 May 18-21; Orlando, FL. ASCO
20. Burns TF et al. (2003) Cell death signaling in malignancy. Cancer Treat Res 115: 319-343
21. Ramaswamy S and Golub TR (2002) DNA microarrays in clinical oncology. J Clin Oncol 20: 1932-1941
22. de Bolle X and Bayliss CD (2003) Gene expression technology. Methods Mol Med 71: 135-146
23. Walker SJ et al. (2003) Semiquantitative real-time PCR for analysis of mRNA levels. Methods Mol Med 79: 211-227
24. Rajeevan MS et al. (2001) Validation of array-based gene expression profiles by real-time (kinetic) RT-PCR. J Mol Diagn 3: 26-31
25. Baunoch D et al.: Microarray analysis of formalin fixed paraffin-embedded tissue: the development of a gene expression staging system for breast carcinoma. In San Antonio Breast Cancer Symposium; 2003 December 3-6; San Antonio, TX. Edited by Lippman ME. Kluwer Academic
26. Paik S et al.: Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients-NSABP studies B-20 and B-14. In San Antonio Breast Cancer Symposium; 2003 December 3-6; San Antonio, TX. Edited by Lippman ME. Kluwer Academic
27. Simon R et al. (2003) Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95: 14-18
28. Cui X and Churchill GA (2003) Statistical tests for differential expression in cDNA microarray experiments. Genome Biol 4: 210
29. Simon R et al. (2002) Design of studies using DNA microarrays. Genet Epidemiol 23: 21-36
30. Sotiriou C et al. (2002) Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 4: R3
31. Assersohn L et al. (2002) The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analyses. Clin Cancer Res 8: 794-801
32. Pusztai L et al. (2003) Gene expression profiles obtained from single passage fine needle aspirations (FNA) of breast cancer reliably identify prognostic/predictive markers such as estrogen (ER) and HER-2 receptor status and reveal large scale molecular differences between ER-negative and ER-positive tumors. Clin Cancer Res 9: 2406-2415
33. Ellis M et al. (2002) Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. Clin Cancer Res 8: 1155-1166
34. Symmans WF et al. (2003) Fine needle aspiration and core needle biopsy samples of breast cancer provide similar total RNA yield, but different stromal gene expression profiles cancer. Cancer 97: 2960-2971
35. Radmacher MD et al. (2002) A paradigm for class prediction using gene expression profiles. J Comput Biol 9: 505-511
36. Chang JC et al. (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362: 362-369
37. Ayers M et al. (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. J Clin Oncol 22: 2284-2293
38. Gianni L: In Proceedings of 40th Annual American Society of Clinical Oncology Meeting; 2004 June 5-8; New Orleans. Edited by Grunberg SN. ASCO
39. Yoshimoto M: In Proceedings of 40th Annual American Society of Clinical Oncology Meeting; 2004 June 5-8; New Orleans. Edited by Grunberg SN. ASCO
40. Hannemann J: In Proceedings of 40th Annual American Society of Clinical Oncology Meeting; 2004 June 5-8; New Orleans. Edited by Grunberg SN. ASCO
41. Buchholz TA et al. (2002) Global gene expression changes during neoadjuvant chemotherapy of human breast cancer. Cancer J 8: 461-468
42. Mukherjee S et al. (2003) Estimating dataset size requirements for classifying DNA microarray data. J Comput Biol 10: 119-42
43. Chakravarthy B and Pietenpol JA (2003) Combined modality management of breast cancer: development of predictive markers through proteomics. Semin Oncol 30 (4 Suppl 9): 23-36
44. Fusaro VA and Stone JH (2003) Mass spectrometry-based proteomics and analyses of serum: a primer for the clinical investigator. Clin Exp Rheumatol 21 (6 Suppl 32): S3-S14
45. Pusztai L et al. (2004) Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 100: 1814-1822